Only in 2025, fifty novel drugs were identified throughout Europe, many classified as potent synthetic opioids. Can the EU’s drug policy adapt fast enough to an increasingly hazardous and rapidly evolving drug market?
On average, a new psychoactive substance emerges on Europe’s drug scene roughly every week. Authorities within the EU emphasize that synthetic opioids present such a critical threat that just a single gram can encompass thousands of potentially fatal doses.
ADVERTISEMENT 
ADVERTISEMENT
This alert comes from the European Union Drugs Agency (EUDA), which released its 2026 European Drug Report on June 9th. The analysis revealed that in 2025 alone, 50 newly detected substances appeared across Europe, predominantly synthetic opioids and cathinones.
The agency currently tracks over 1,000 novel psychoactive compounds through its Early Warning System, including more than 100 synthetic opioids—a group that was nearly absent ten years ago.
Notably, the emerging category of «orphine» opioids, semi-synthetic derivatives that have expanded swiftly since 2024, constitutes a fresh threat. Nine new orphine variants have been identified, implicated in upwards of 30 fatalities continent-wide. Among these, cychlorphine and spirochlorphine have surfaced in over a dozen countries and are undergoing expedited EU-wide risk evaluations.
«Pinpointing a single cause is difficult, as the market adapts to multiple influences,» EUDA Executive Director Lorraine Nolan explained during an interview, highlighting factors like organised crime, migration trends, and geopolitical changes reshaping the drug supply landscape. She added that Europe has evolved into a manufacturing hub, with hundreds of illicit labs operating yearly, leveraging the continent’s amphetamine-producing heritage and advanced equipment.
«The challenge lies in the rapid pace of innovation and the swift introduction of new substances,» Nolan said, emphasizing that each novel compound carries health risks that remain largely uncharted.
Despite these hurdles, Europe is not falling behind. In July 2024, the EUDA’s mandate was enhanced, leading to the deployment of several mechanisms to narrow the gap between identification and regulation: a European Drug Alert System to issue timely field warnings, a threat-assessment unit predicting new substances’ impacts, and a network of forensic and toxicology labs.
Concerning synthetic opioids, the agency is actively conducting risk evaluations on multiple substances likely to undergo EU-wide regulatory control, aiming for a streamlined process from quick detection to harm characterization and subsequent regulation.
Data from the EUDA report indicate that the EU is faring better compared to some other regions. In 2024, the EU documented roughly 7,600 drug-related fatalities, a small fraction relative to the more than 100,000 annual deaths reported in the United States, whose population is smaller.
Nolan attributed this discrepancy partly to Europe’s «balanced approach,» combining enforcement measures with consistent investment in treatment programs and harm reduction. Approximately 60 percent—over 500,000—of the EU’s estimated 800,000 problematic opioid users now benefit from opioid agonist therapy, while take-home naloxone, the antidote for overdoses, is accessible in 19 member states.
Nonetheless, gaps persist. Needle and syringe programs operate broadly across the EU, but several member countries still do not meet international coverage standards. Facilities for supervised drug consumption—a more debated harm reduction strategy—are expanding only slowly. Nolan described the overall progress as «an aggressively improving situation,» reliant on national systems that, while committed, are funded unevenly.
This unevenness is central to the new 2026-2030 EU Drugs Strategy, ratified by the Council in June, representing one of the continent’s most comprehensive policy frameworks. The strategy revolves around five pillars: public health, security, harm reduction, partnerships, and preparedness.
The objective is to move beyond what Nolan perceives as a flawed tradition of policy that treated supply and demand separately. «It actually considers thoroughly the complex interaction between these two elements,» she noted.
Within this strategy, the EUDA’s function remains technical rather than enforcement-focused. The agency delivers evidence, training, and surveillance support, enabling governments to formulate effective policies instead of imposing directives. Last year, it trained thousands of frontline workers and conducted over 1,200 webinars for national officials.
Collaboration with Europol and Frontex is intensifying, Nolan said, as trafficking networks become more complex and increasingly connected with organised violence. Presently, the EUDA holds presidency over the EU’s Justice and Home Affairs agencies network, with this year’s agenda emphasizing the intersection of health, security, and emerging technological threats.
Brussels is betting that faster detection, accelerated risk analysis, and ongoing expenditure on harm reduction can prevent Europe’s opioid crisis from mirroring trajectories observed elsewhere, even as the chemical nature of the threat continues to evolve.